Monthly Archives: June 2010

AZ Celebrates Crestor Patent Win

The US District Court in Delaware upheld AstraZeneca’s patent for its blockbuster statin Crestor (rosuvastatin), ending a dispute that could have crippled the drugmaker’s billion-dollar cash cow. Crestor’s patent is not scheduled to expire until 2016. However, a group of generics firms had claimed that a substance patent (314) protecting one of the active ingredients […]
Posted in Legal | Tagged , , , , , , , | Leave a comment

GSK Scores High in Market Access

GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity […]
Posted in Emerging Markets, Strategy | Tagged , , , , , , , | Leave a comment

HTA Concerns From European Drug Agency

The EMA’s Thomas Lönngren has gone public with his disquiet over organizations such as NICE. But pharma still needs more allies in fighting what it sees as the failings of the health technology assessment bodies, says Pharm Exec Europe‘s Brussels correspondent, Reflector. Europe’s pharmaceutical firms were never very keen on Britain’s influential National Institute for […]
Posted in Europe, Global, Guest Blog, Regulatory, Safety, Strategy | Tagged , , , , | Leave a comment

Pharma and Cloud Computing: Are We There Yet?

In the past few years, Microsoft has been working hard to create clinical trial platforms for the pharmaceutical industry. This year, the Redmond, WA-based behemoth has moved full-speed ahead with its virtual-server system, dubbed Azure. Microsoft is not only working on hosted applications, instead the company has established a massive online server or “cloud” that […]
Posted in Technology | Tagged , , , , | 1 Comment

Industry and FDA Brace for Change

While the convention floor of the 46th annual meeting of the Drug Information Association bustled with the usual vendors touting the latest and greatest clinical trial technology, the panels (particularly those that featured FDA members) had a remarkably somber tone. The main refrain was: “Things are going to change and everyone must step up or […]
Posted in Regulatory, Strategy | Tagged , , , , , , | 1 Comment
  • Categories

  • Meta